| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human PRAG1 recombinant protein (Position: H2-V1104) was used as the immunogen for the PRAG1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
PRAG1 Antibody / Pragmin / PEAK1-related kinase-activating pseudokinase 1 is a anti-PRAG1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF), Flow cytometry (FACS), ELISA with listed reactivity in Human. Reported localization: Nucleus, Cell Junctions, possible Cytoplasm.
Key elements and design rationale
- Target: PRAG1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ICC, IF, FACS, ELISA
Biological background
Structurally, PRAG1 contains an N-terminal actin-binding domain, a proline-rich region that interacts with SH3 domain-containing proteins, and multiple tyrosine phosphorylation motifs that recruit Src family kinases. Although it lacks intrinsic kinase activity, PRAG1 serves as a platform that enhances activation of FAK, Src, and downstream MAPK signaling, linking mechanical and biochemical cues during adhesion turnover. Its localization to focal adhesions and actin stress fibers reflects its role in maintaining cellular structure and migration capacity.
The PRAG1 antibody is widely used in cancer, developmental biology, and cytoskeletal signaling research to investigate adhesion signaling, actin dynamics, and metastatic potential. Western blot analysis detects a 170 kilodalton band corresponding to PRAG1, while immunofluorescence shows peripheral staining at focal adhesion sites and along actin filaments. This antibody supports studies examining integrin-mediated signaling and tumor cell invasion mechanisms.
Aberrant expression of PRAG1 contributes to epithelial-mesenchymal transition (EMT), tumor metastasis, and angiogenesis. Elevated PRAG1 levels enhance migration and invasion by promoting FAK/Src complex activation and actin remodeling. Conversely, depletion of PRAG1 suppresses motility and reduces metastatic spread. The PRAG1 antibody provides an essential tool for dissecting these molecular pathways and evaluating PRAG1 as a potential therapeutic target in oncology.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
